Loading…
Evaluate the Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) Program in Saudi Arabia: A Retrospective Study
(1) Background: Outpatient parenteral antibiotic therapy (OPAT) is a well-established and cost-effective measure that improves the efficient use of healthcare resources and increases bed availability. Only limited published data is available to illustrate OPAT implementation and outcomes in Saudi Ar...
Saved in:
Published in: | Antibiotics (Basel) 2022-03, Vol.11 (4), p.441 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c499t-b8efda22592d7d11ed72079206f2861ef974c18ef9e345106d3d6a509e3fa2993 |
---|---|
cites | cdi_FETCH-LOGICAL-c499t-b8efda22592d7d11ed72079206f2861ef974c18ef9e345106d3d6a509e3fa2993 |
container_end_page | |
container_issue | 4 |
container_start_page | 441 |
container_title | Antibiotics (Basel) |
container_volume | 11 |
creator | Al Shareef, Haneen J Al Harbi, Adnan Alatawi, Yasser Aljabri, Ahmed Al-Ghanmi, Mohammed A Alzahrani, Mohammed S Algarni, Majed Ahmed Khobrani, Attiah Haseeb, Abdul AlSenani, Faisal Elrggal, Mahmoud E |
description | (1) Background: Outpatient parenteral antibiotic therapy (OPAT) is a well-established and cost-effective measure that improves the efficient use of healthcare resources and increases bed availability. Only limited published data is available to illustrate OPAT implementation and outcomes in Saudi Arabia. The main objective of this study was to evaluate the effectiveness of OPAT in a tertiary center in Saudi Arabia. (2) Methods: In this retrospective study, clinical charts of enrolled patients were reviewed in a tertiary care center from the initial month of November 2017 to March 2020. All admitted patients with a central line and who enrolled in the OPAT of the hospital during this study period were included. The primary outcome was the 30-days readmission rate of OPAT patients. Secondary outcomes were factors associated with OPAT failure. Descriptive analysis of the data was used to express the results. (3) Results: We enrolled 90 patients; 54 (60%) were male; the mean age was 55.16 (±17.7) years old. The mean duration of the antimicrobial treatment was 21.9 (+24.6) days. All patients completed the intended course of therapy. Ertapenem was the most frequently used antimicrobial (43%), followed by vancomycin (11.2%). Urinary tract infections (UTIs) are some of the most common bacterial infections in 25 patients (26.9%), followed by osteomyelitis in 16 patients (17.2%). Extended-spectrum beta-lactamase
was the highest common isolated microorganism (44.9%), followed by methicillin-resistant Staphylococcus aureus MRSA (16.9%). The readmission to the hospital during therapy was required for 12 patients (13.3%). Shifting from hospital care to OPAT care resulted in cost savings of 18 million SAR in the overall assessment period and avoided a total of 1984 patient days of hospitalization. (4) Conclusion: The findings have shown that OPAT therapy was effective with minimum hospital readmissions and therapy complications. OPAT programs can reduce healthcare costs and should be integrated into practice. |
doi_str_mv | 10.3390/antibiotics11040441 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_75358d6938864205b8d8c6b4d5206c5b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_75358d6938864205b8d8c6b4d5206c5b</doaj_id><sourcerecordid>2652948983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-b8efda22592d7d11ed72079206f2861ef974c18ef9e345106d3d6a509e3fa2993</originalsourceid><addsrcrecordid>eNptUk1rGzEQXUpLE9z8gkIR9JIc3Op7pR4KS3DaQMCmcc9Cu9LaMrurraQ1-NS_XjlOQ1Kqy2hGb97MPE1RvEfwEyESftZDcrXzyTURIUghpehVcY5hKeecCPz62f2suIhxB_ORiAgo3hZnhFFGkMTnxe_FXneTThakrQWLtrVNcns72BiBb8FySqNOzg4JrHTIxgbdgSoX710TfO2yt97m4HgAl8tVtb4Cq-A3QffADeBeT8aBKuiM-wIq8MOm4ON4KgHu02QO74o3re6ivXi0s-LnzWJ9_X1-t_x2e13dzRsqZZrXwrZGY8wkNqVByJryOB-GvMWCI9vKkjYog6QllCHIDTFcM5jdVmMpyay4PfEar3dqDK7X4aC8duoh4MNG6ZDV7KwqGWHCcEmE4BRDVgsjGl5Tw3K5htWZ6-uJa5zq3pomy5JVeUH68mVwW7XxeyUh5oKSTHD5SBD8r8nGpHoXG9t1erB-igpzRrFELHcyKz7-A935KQxZqiMKSyqkOBKSEyr_SYzBtk_NIKiO-6L-sy8568PzOZ5y_m4H-QO__L7I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2652948983</pqid></control><display><type>article</type><title>Evaluate the Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) Program in Saudi Arabia: A Retrospective Study</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>Coronavirus Research Database</source><creator>Al Shareef, Haneen J ; Al Harbi, Adnan ; Alatawi, Yasser ; Aljabri, Ahmed ; Al-Ghanmi, Mohammed A ; Alzahrani, Mohammed S ; Algarni, Majed Ahmed ; Khobrani, Attiah ; Haseeb, Abdul ; AlSenani, Faisal ; Elrggal, Mahmoud E</creator><creatorcontrib>Al Shareef, Haneen J ; Al Harbi, Adnan ; Alatawi, Yasser ; Aljabri, Ahmed ; Al-Ghanmi, Mohammed A ; Alzahrani, Mohammed S ; Algarni, Majed Ahmed ; Khobrani, Attiah ; Haseeb, Abdul ; AlSenani, Faisal ; Elrggal, Mahmoud E</creatorcontrib><description>(1) Background: Outpatient parenteral antibiotic therapy (OPAT) is a well-established and cost-effective measure that improves the efficient use of healthcare resources and increases bed availability. Only limited published data is available to illustrate OPAT implementation and outcomes in Saudi Arabia. The main objective of this study was to evaluate the effectiveness of OPAT in a tertiary center in Saudi Arabia. (2) Methods: In this retrospective study, clinical charts of enrolled patients were reviewed in a tertiary care center from the initial month of November 2017 to March 2020. All admitted patients with a central line and who enrolled in the OPAT of the hospital during this study period were included. The primary outcome was the 30-days readmission rate of OPAT patients. Secondary outcomes were factors associated with OPAT failure. Descriptive analysis of the data was used to express the results. (3) Results: We enrolled 90 patients; 54 (60%) were male; the mean age was 55.16 (±17.7) years old. The mean duration of the antimicrobial treatment was 21.9 (+24.6) days. All patients completed the intended course of therapy. Ertapenem was the most frequently used antimicrobial (43%), followed by vancomycin (11.2%). Urinary tract infections (UTIs) are some of the most common bacterial infections in 25 patients (26.9%), followed by osteomyelitis in 16 patients (17.2%). Extended-spectrum beta-lactamase
was the highest common isolated microorganism (44.9%), followed by methicillin-resistant Staphylococcus aureus MRSA (16.9%). The readmission to the hospital during therapy was required for 12 patients (13.3%). Shifting from hospital care to OPAT care resulted in cost savings of 18 million SAR in the overall assessment period and avoided a total of 1984 patient days of hospitalization. (4) Conclusion: The findings have shown that OPAT therapy was effective with minimum hospital readmissions and therapy complications. OPAT programs can reduce healthcare costs and should be integrated into practice.</description><identifier>ISSN: 2079-6382</identifier><identifier>EISSN: 2079-6382</identifier><identifier>DOI: 10.3390/antibiotics11040441</identifier><identifier>PMID: 35453192</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibiotics ; Antiinfectives and antibacterials ; Antimicrobial agents ; antimicrobial stewardship ; antimicrobials ; Bacterial diseases ; Biomedical materials ; Complications ; Cost control ; Drug resistance ; E coli ; Ertapenem ; Evaluation ; Failure analysis ; Health care expenditures ; Health care policy ; Hospitalization ; Hospitals ; Infections ; Infectious diseases ; Length of stay ; Methicillin ; Nosocomial infections ; Osteomyelitis ; outpatients ; parenteral ; Patient satisfaction ; Patients ; Public health ; Staphylococcus aureus ; Therapy ; Urinary tract ; Urogenital system ; Vancomycin ; β Lactamase</subject><ispartof>Antibiotics (Basel), 2022-03, Vol.11 (4), p.441</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-b8efda22592d7d11ed72079206f2861ef974c18ef9e345106d3d6a509e3fa2993</citedby><cites>FETCH-LOGICAL-c499t-b8efda22592d7d11ed72079206f2861ef974c18ef9e345106d3d6a509e3fa2993</cites><orcidid>0000-0003-2455-5054 ; 0000-0001-8167-6931 ; 0000-0002-0026-5514 ; 0000-0002-7267-9636 ; 0000-0001-9028-9415 ; 0000-0002-4192-1653</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2652948983?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2652948983?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35453192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al Shareef, Haneen J</creatorcontrib><creatorcontrib>Al Harbi, Adnan</creatorcontrib><creatorcontrib>Alatawi, Yasser</creatorcontrib><creatorcontrib>Aljabri, Ahmed</creatorcontrib><creatorcontrib>Al-Ghanmi, Mohammed A</creatorcontrib><creatorcontrib>Alzahrani, Mohammed S</creatorcontrib><creatorcontrib>Algarni, Majed Ahmed</creatorcontrib><creatorcontrib>Khobrani, Attiah</creatorcontrib><creatorcontrib>Haseeb, Abdul</creatorcontrib><creatorcontrib>AlSenani, Faisal</creatorcontrib><creatorcontrib>Elrggal, Mahmoud E</creatorcontrib><title>Evaluate the Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) Program in Saudi Arabia: A Retrospective Study</title><title>Antibiotics (Basel)</title><addtitle>Antibiotics (Basel)</addtitle><description>(1) Background: Outpatient parenteral antibiotic therapy (OPAT) is a well-established and cost-effective measure that improves the efficient use of healthcare resources and increases bed availability. Only limited published data is available to illustrate OPAT implementation and outcomes in Saudi Arabia. The main objective of this study was to evaluate the effectiveness of OPAT in a tertiary center in Saudi Arabia. (2) Methods: In this retrospective study, clinical charts of enrolled patients were reviewed in a tertiary care center from the initial month of November 2017 to March 2020. All admitted patients with a central line and who enrolled in the OPAT of the hospital during this study period were included. The primary outcome was the 30-days readmission rate of OPAT patients. Secondary outcomes were factors associated with OPAT failure. Descriptive analysis of the data was used to express the results. (3) Results: We enrolled 90 patients; 54 (60%) were male; the mean age was 55.16 (±17.7) years old. The mean duration of the antimicrobial treatment was 21.9 (+24.6) days. All patients completed the intended course of therapy. Ertapenem was the most frequently used antimicrobial (43%), followed by vancomycin (11.2%). Urinary tract infections (UTIs) are some of the most common bacterial infections in 25 patients (26.9%), followed by osteomyelitis in 16 patients (17.2%). Extended-spectrum beta-lactamase
was the highest common isolated microorganism (44.9%), followed by methicillin-resistant Staphylococcus aureus MRSA (16.9%). The readmission to the hospital during therapy was required for 12 patients (13.3%). Shifting from hospital care to OPAT care resulted in cost savings of 18 million SAR in the overall assessment period and avoided a total of 1984 patient days of hospitalization. (4) Conclusion: The findings have shown that OPAT therapy was effective with minimum hospital readmissions and therapy complications. OPAT programs can reduce healthcare costs and should be integrated into practice.</description><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Antimicrobial agents</subject><subject>antimicrobial stewardship</subject><subject>antimicrobials</subject><subject>Bacterial diseases</subject><subject>Biomedical materials</subject><subject>Complications</subject><subject>Cost control</subject><subject>Drug resistance</subject><subject>E coli</subject><subject>Ertapenem</subject><subject>Evaluation</subject><subject>Failure analysis</subject><subject>Health care expenditures</subject><subject>Health care policy</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Length of stay</subject><subject>Methicillin</subject><subject>Nosocomial infections</subject><subject>Osteomyelitis</subject><subject>outpatients</subject><subject>parenteral</subject><subject>Patient satisfaction</subject><subject>Patients</subject><subject>Public health</subject><subject>Staphylococcus aureus</subject><subject>Therapy</subject><subject>Urinary tract</subject><subject>Urogenital system</subject><subject>Vancomycin</subject><subject>β Lactamase</subject><issn>2079-6382</issn><issn>2079-6382</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1rGzEQXUpLE9z8gkIR9JIc3Op7pR4KS3DaQMCmcc9Cu9LaMrurraQ1-NS_XjlOQ1Kqy2hGb97MPE1RvEfwEyESftZDcrXzyTURIUghpehVcY5hKeecCPz62f2suIhxB_ORiAgo3hZnhFFGkMTnxe_FXneTThakrQWLtrVNcns72BiBb8FySqNOzg4JrHTIxgbdgSoX710TfO2yt97m4HgAl8tVtb4Cq-A3QffADeBeT8aBKuiM-wIq8MOm4ON4KgHu02QO74o3re6ivXi0s-LnzWJ9_X1-t_x2e13dzRsqZZrXwrZGY8wkNqVByJryOB-GvMWCI9vKkjYog6QllCHIDTFcM5jdVmMpyay4PfEar3dqDK7X4aC8duoh4MNG6ZDV7KwqGWHCcEmE4BRDVgsjGl5Tw3K5htWZ6-uJa5zq3pomy5JVeUH68mVwW7XxeyUh5oKSTHD5SBD8r8nGpHoXG9t1erB-igpzRrFELHcyKz7-A935KQxZqiMKSyqkOBKSEyr_SYzBtk_NIKiO-6L-sy8568PzOZ5y_m4H-QO__L7I</recordid><startdate>20220324</startdate><enddate>20220324</enddate><creator>Al Shareef, Haneen J</creator><creator>Al Harbi, Adnan</creator><creator>Alatawi, Yasser</creator><creator>Aljabri, Ahmed</creator><creator>Al-Ghanmi, Mohammed A</creator><creator>Alzahrani, Mohammed S</creator><creator>Algarni, Majed Ahmed</creator><creator>Khobrani, Attiah</creator><creator>Haseeb, Abdul</creator><creator>AlSenani, Faisal</creator><creator>Elrggal, Mahmoud E</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2455-5054</orcidid><orcidid>https://orcid.org/0000-0001-8167-6931</orcidid><orcidid>https://orcid.org/0000-0002-0026-5514</orcidid><orcidid>https://orcid.org/0000-0002-7267-9636</orcidid><orcidid>https://orcid.org/0000-0001-9028-9415</orcidid><orcidid>https://orcid.org/0000-0002-4192-1653</orcidid></search><sort><creationdate>20220324</creationdate><title>Evaluate the Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) Program in Saudi Arabia: A Retrospective Study</title><author>Al Shareef, Haneen J ; Al Harbi, Adnan ; Alatawi, Yasser ; Aljabri, Ahmed ; Al-Ghanmi, Mohammed A ; Alzahrani, Mohammed S ; Algarni, Majed Ahmed ; Khobrani, Attiah ; Haseeb, Abdul ; AlSenani, Faisal ; Elrggal, Mahmoud E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-b8efda22592d7d11ed72079206f2861ef974c18ef9e345106d3d6a509e3fa2993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Antimicrobial agents</topic><topic>antimicrobial stewardship</topic><topic>antimicrobials</topic><topic>Bacterial diseases</topic><topic>Biomedical materials</topic><topic>Complications</topic><topic>Cost control</topic><topic>Drug resistance</topic><topic>E coli</topic><topic>Ertapenem</topic><topic>Evaluation</topic><topic>Failure analysis</topic><topic>Health care expenditures</topic><topic>Health care policy</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Length of stay</topic><topic>Methicillin</topic><topic>Nosocomial infections</topic><topic>Osteomyelitis</topic><topic>outpatients</topic><topic>parenteral</topic><topic>Patient satisfaction</topic><topic>Patients</topic><topic>Public health</topic><topic>Staphylococcus aureus</topic><topic>Therapy</topic><topic>Urinary tract</topic><topic>Urogenital system</topic><topic>Vancomycin</topic><topic>β Lactamase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al Shareef, Haneen J</creatorcontrib><creatorcontrib>Al Harbi, Adnan</creatorcontrib><creatorcontrib>Alatawi, Yasser</creatorcontrib><creatorcontrib>Aljabri, Ahmed</creatorcontrib><creatorcontrib>Al-Ghanmi, Mohammed A</creatorcontrib><creatorcontrib>Alzahrani, Mohammed S</creatorcontrib><creatorcontrib>Algarni, Majed Ahmed</creatorcontrib><creatorcontrib>Khobrani, Attiah</creatorcontrib><creatorcontrib>Haseeb, Abdul</creatorcontrib><creatorcontrib>AlSenani, Faisal</creatorcontrib><creatorcontrib>Elrggal, Mahmoud E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Antibiotics (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al Shareef, Haneen J</au><au>Al Harbi, Adnan</au><au>Alatawi, Yasser</au><au>Aljabri, Ahmed</au><au>Al-Ghanmi, Mohammed A</au><au>Alzahrani, Mohammed S</au><au>Algarni, Majed Ahmed</au><au>Khobrani, Attiah</au><au>Haseeb, Abdul</au><au>AlSenani, Faisal</au><au>Elrggal, Mahmoud E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluate the Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) Program in Saudi Arabia: A Retrospective Study</atitle><jtitle>Antibiotics (Basel)</jtitle><addtitle>Antibiotics (Basel)</addtitle><date>2022-03-24</date><risdate>2022</risdate><volume>11</volume><issue>4</issue><spage>441</spage><pages>441-</pages><issn>2079-6382</issn><eissn>2079-6382</eissn><abstract>(1) Background: Outpatient parenteral antibiotic therapy (OPAT) is a well-established and cost-effective measure that improves the efficient use of healthcare resources and increases bed availability. Only limited published data is available to illustrate OPAT implementation and outcomes in Saudi Arabia. The main objective of this study was to evaluate the effectiveness of OPAT in a tertiary center in Saudi Arabia. (2) Methods: In this retrospective study, clinical charts of enrolled patients were reviewed in a tertiary care center from the initial month of November 2017 to March 2020. All admitted patients with a central line and who enrolled in the OPAT of the hospital during this study period were included. The primary outcome was the 30-days readmission rate of OPAT patients. Secondary outcomes were factors associated with OPAT failure. Descriptive analysis of the data was used to express the results. (3) Results: We enrolled 90 patients; 54 (60%) were male; the mean age was 55.16 (±17.7) years old. The mean duration of the antimicrobial treatment was 21.9 (+24.6) days. All patients completed the intended course of therapy. Ertapenem was the most frequently used antimicrobial (43%), followed by vancomycin (11.2%). Urinary tract infections (UTIs) are some of the most common bacterial infections in 25 patients (26.9%), followed by osteomyelitis in 16 patients (17.2%). Extended-spectrum beta-lactamase
was the highest common isolated microorganism (44.9%), followed by methicillin-resistant Staphylococcus aureus MRSA (16.9%). The readmission to the hospital during therapy was required for 12 patients (13.3%). Shifting from hospital care to OPAT care resulted in cost savings of 18 million SAR in the overall assessment period and avoided a total of 1984 patient days of hospitalization. (4) Conclusion: The findings have shown that OPAT therapy was effective with minimum hospital readmissions and therapy complications. OPAT programs can reduce healthcare costs and should be integrated into practice.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35453192</pmid><doi>10.3390/antibiotics11040441</doi><orcidid>https://orcid.org/0000-0003-2455-5054</orcidid><orcidid>https://orcid.org/0000-0001-8167-6931</orcidid><orcidid>https://orcid.org/0000-0002-0026-5514</orcidid><orcidid>https://orcid.org/0000-0002-7267-9636</orcidid><orcidid>https://orcid.org/0000-0001-9028-9415</orcidid><orcidid>https://orcid.org/0000-0002-4192-1653</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2079-6382 |
ispartof | Antibiotics (Basel), 2022-03, Vol.11 (4), p.441 |
issn | 2079-6382 2079-6382 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_75358d6938864205b8d8c6b4d5206c5b |
source | PubMed (Medline); Publicly Available Content Database; Coronavirus Research Database |
subjects | Antibiotics Antiinfectives and antibacterials Antimicrobial agents antimicrobial stewardship antimicrobials Bacterial diseases Biomedical materials Complications Cost control Drug resistance E coli Ertapenem Evaluation Failure analysis Health care expenditures Health care policy Hospitalization Hospitals Infections Infectious diseases Length of stay Methicillin Nosocomial infections Osteomyelitis outpatients parenteral Patient satisfaction Patients Public health Staphylococcus aureus Therapy Urinary tract Urogenital system Vancomycin β Lactamase |
title | Evaluate the Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) Program in Saudi Arabia: A Retrospective Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A47%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluate%20the%20Effectiveness%20of%20Outpatient%20Parenteral%20Antimicrobial%20Therapy%20(OPAT)%20Program%20in%20Saudi%20Arabia:%20A%20Retrospective%20Study&rft.jtitle=Antibiotics%20(Basel)&rft.au=Al%20Shareef,%20Haneen%20J&rft.date=2022-03-24&rft.volume=11&rft.issue=4&rft.spage=441&rft.pages=441-&rft.issn=2079-6382&rft.eissn=2079-6382&rft_id=info:doi/10.3390/antibiotics11040441&rft_dat=%3Cproquest_doaj_%3E2652948983%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-b8efda22592d7d11ed72079206f2861ef974c18ef9e345106d3d6a509e3fa2993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2652948983&rft_id=info:pmid/35453192&rfr_iscdi=true |